Craig-Hallum Maintains Buy on MapLight Therapeutics, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 60.9%

Neg 60.9% Neu 0% Pos 0%

Craig-Hallum analyst Adam Vogel maintains MapLight Therapeutics (NASDAQ:MPLT) with a Buy and lowers the price target from $43 to $40.